| Cited nodes | Nodes / Authors | GCS | LCS |
| 1 | 4 1997 JOURNAL OF HEALTH ECONOMICS 16(1):33-64
Meltzer D
Accounting for future costs in medical cost-effectiveness analysis | 74 | 74
|
| 2 | 14 1998 MEDICAL DECISION MAKING 18(2):S68-S80
Stinnett AA; Mullahy J
Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis | 46 | 3
|
| 0 | 1 1992 CANCER 69(7):1957-1962
MUSHLIN AI; FINTOR L
IS SCREENING FOR BREAST-CANCER COST-EFFECTIVE | 45 | 3
|
| 1 | 9 1998 ARCHIVES OF GENERAL PSYCHIATRY 55(7):645-651
Lave JR; Frank RG; Schulberg HC; Kamlet MS
Cost-effectiveness of treatments for major depression in primary care practice | 39 | 1
|
| 1 | 16 1998 PHARMACOECONOMICS 13(1):1-7
Liljas B
How to calculate indirect costs in economic evaluations | 28 | 3
|
| 1 | 7 1997 MEDICAL DECISION MAKING 17(4):382-389
Johannesson M; Meltzer D; OConor RM
Incorporating future costs in medical cost-effectiveness analysis: Implications for the cost-effectiveness of the treatment of hypertension | 25 | 12
|
| 2 | 10 1998 HEALTH ECONOMICS 7(1):1-7
Johannesson M; Meltzer D
Some reflections on cost-effectiveness analysis | 25 | 7
|
| 2 | 32 1999 OSTEOPOROSIS INTERNATIONAL 10(3):193-199
Jonsson B; Kanis J; Dawson A; Oden A; Johnell O
Effect and offset of effect of treatments for hip fracture on health outcomes | 22 | 2
|
| 1 | 5 1997 JOURNAL OF HEALTH ECONOMICS 16(1):121-128
Weinstein MC; Manning WG
Theoretical issues in cost-effectiveness analysis | 18 | 14
|
| 1 | 6 1997 JOURNAL OF HEALTH ECONOMICS 16(6):749-757
Kenkel D
On valuing morbidity, cost-effectiveness analysis, and being rude | 18 | 1
|
| 2 | 11 1998 HEALTH ECONOMICS 7(1):9-20
Gyrd-Hansen D; Sogaard J; Kronborg O
Colorectal cancer screening: Efficiency and effectiveness | 18 | 0
|
| 1 | 27 1999 MEDICAL CARE 37(12):1249-1259
Brown ML; Riley GF; Potosky AL; Etzioni RD
Obtaining long-term disease specific costs of care - Application to Medicare enrollees diagnosed with colorectal cancer | 17 | 2
|
| 1 | 8 1997 MEDICAL DECISION MAKING 17(4):483-489
Stinnett AA; Paltiel AD
Estimating CE ratios under second-order uncertainty: The mean ratio versus the ratio of means | 13 | 4
|
| 1 | 12 1998 INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 14(2):255-267
Zethraeus N; Gerdtham UG
Estimating the costs of hip fracture and potential savings | 13 | 3
|
| 2 | 48 2001 ARCHIVES OF GENERAL PSYCHIATRY 58(2):181-187
Simon GE; Manning WG; Katzelnick DJ; Pearson SD; Henk HJ; Helstad CP
Cost-effectiveness of systematic depression treatment for high utilizers of general medical care | 11 | 0
|
| 0 | 3 1997 INDIANA LAW JOURNAL 72(4):1015-1097
Rai AK
Rationing through choice: A new approach to cost-effectiveness analysis in health care | 9 | 0
|
| 1 | 13 1998 MEDICAL CARE RESEARCH AND REVIEW 55(3):259-288
Chernew ME; Hirth RA; Sonnad SS; Ermann R; Fendrick AM
Managed care, medical technology, and health care cost growth: A review of the evidence | 9 | 0
|
| 2 | 43 2000 PHARMACOECONOMICS 17(5):479-500
Briggs AH
Handling uncertainty in cost-effectiveness models | 9 | 0
|
| 1 | 20 1998 QUARTERLY JOURNAL OF ECONOMICS 113(4):991-1024
Cutler DM; McClellan M; Newhouse JP; Remler D
Are medical prices declining? Evidence from heart attack treatments | 8 | 1
|
| 3 | 26 1999 JOURNAL OF HEALTH ECONOMICS 18(6):681-708
Bleichrodt H; Quiggin J
Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? | 8 | 1
|
| 3 | 35 2000 EUROPEAN HEART JOURNAL 21(9):733-739
Almbrand B; Johannesson M; Sjostrand B; Malmberg K; Ryden L
Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus - Results from the DIGAMI study | 8 | 2
|
| 4 | 37 2000 INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 16(1):111-124
Stone PW; Chapman RH; Sandberg EA; Liljas B; Neumann PJ
Measuring costs in cost-utility analyses - Variations in the literature | 8 | 1
|
| 1 | 17 1998 PHARMACOECONOMICS 13(4):389-396
Donaldson C
The (near)equivalence of cost-effectiveness and cost-benefit analyses - Fact or fallacy? | 7 | 1
|
| 3 | 23 1999 HEALTH ECONOMICS 8(2):171-174
Laska EM; Meisner M; Siegel C; Stinnett AA
Ratio-based and net benefit-based approaches to health care resource allocation: Proofs of optimality and equivalence | 7 | 0
|
| 3 | 28 1999 MEDICAL DECISION MAKING 19(4):371-377
Meltzer D; Johannesson M
Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine | 7 | 3
|
| 1 | 33 1999 PHARMACOECONOMICS 16(5):459-472
Cremieux PY; Finkelstein SN; Berndt ER; Crawford J; Slavin MB
Cast effectiveness, quality-adjusted life-years and supportive care - Recombinant human erythropoietin as a treatment of cancer-associated anaemia | 7 | 0
|
| 3 | 38 2000 JOURNAL OF HEALTH ECONOMICS 19(4):439-459
Brouwer WBF; Koopmanschap MA
On the economic foundations of CEA. Ladies and gentlemen, take your positions! | 6 | 1
|
| 3 | 60 2001 OSTEOPOROSIS INTERNATIONAL 12(5):356-361
Kanis JA; Dawson A; Oden A; Johnell O; de Laet C; Jonsson B
Cost-effectiveness of preventing hip fracture in the general female population | 6 | 1
|
| 1 | 34 2000 DEMOGRAPHY 37(3):253-265
Manton KG; Land KC
Active life expectancy estimates for the US elderly population: A multidimensional continuous-mixture model of functional change applied to completed cohorts, 1982-1996 | 4 | 0
|
| 3 | 40 2000 JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY 163():211-225
Claxton K; Lacey LF; Walker SG
Selecting treatments: a decision theoretic approach | 4 | 0
|
| 3 | 41 2000 MEDICAL CARE 38(6):679-685
Meltzer D; Egleston B; Stoffel D; Dasbach E
Effect of future costs on cost-effectiveness of medical interventions among young adults - The example of intensive therapy for type 1 diabetes mellitus | 4 | 1
|
| 1 | 46 2000 REVIEWS IN CONTEMPORARY PHARMACOTHERAPY 11(1):43-62
Luscombe FA
Socioeconomic burden of urinary incontinence with focus on overactive bladder and tolterodine treatment | 4 | 1
|
| 2 | 54 2001 HEALTH ECONOMICS 10(3):245-256
Etzioni R; Ramsey SD; Berry K; Brown M
The impact of including future medical care costs when estimating the costs attributable to a disease: A colorectal cancer case study | 4 | 0
|
| 2 | 24 1999 INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 15(2):352-365
Zethraeus N; Johannesson M; Jonsson B
A computer model to analyze the cost-effectiveness of hormone replacement therapy | 3 | 0
|
| 3 | 50 2001 EUROPEAN HEART JOURNAL 22(11):919-925
Johannesson M
At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? | 3 | 1
|
| 0 | 53 2001 HEALTH AFFAIRS 20(5):11-29
Cutler DM; McClellan M
Is technological change in medicine worth it? | 3 | 0
|
| 4 | 59 2001 LANCET 358(9289):1251-1256
Jonsson B
Economics of drug treatment: for which patients is it costeffective to lower cholesterol? | 3 | 0
|
| 2 | 61 2001 PHARMACOECONOMICS 19(7):709-713
Sendi P; Palmer AJ; Gafni A; Battegay M
Highly active antiretroviral therapy - Pharmacoeconomic issues in the management of HIV infection | 3 | 0
|
| 1 | 15 1998 OSTEOPOROSIS INTERNATIONAL 8():S13-S16
Jonsson B
Targeting high-risk populations | 2 | 0
|
| 2 | 18 1998 PHARMACOECONOMICS 13(5):566-569
Liljas B
How to calculate indirect costs in economic evaluations - The author's reply | 2 | 0
|
| 1 | 19 1998 PSYCHOLOGICAL INQUIRY 9(1):69-85
Ryff CD; Singer B
Human health: New directions for the next millennium | 2 | 0
|
| 2 | 29 1999 MEDICAL DECISION MAKING 19(4):378-379
Garber AM
Comments - Realistic rigor in cost-effectiveness methods | 2 | 1
|
| 2 | 42 2000 PEDIATRICS 105(4):art. no.-e54
Immergluck LC; Cull WL; Schwartz A; Elstein AS
Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago | 2 | 0
|
| 3 | 57 2001 JOURNAL OF HEALTH ECONOMICS 20(1):109-129
Meltzer D
Addressing uncertainty in medical cost-effectiveness analysis - Implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research | 2 | 0
|
| 3 | 31 1999 MEDICAL DECISION MAKING 19(4):383-384
Meltzer D; Johannesson M
Response - On the role of theory in cost-effectiveness analysis - A response to Garber, Russell, and Weinstein | 1 | 0
|
| 1 | 45 2000 RELIABILITY ENGINEERING & SYSTEM SAFETY 67(2):205-209
Ramsberg J
Comments on Bohnenblust and Slovic, and Vrijling, van Hengel and Houben | 1 | 0
|
| 2 | 56 2001 HEALTH ECONOMICS 10(8):751-774
Beutels P
Economic evaluations of hepatitis B immunization: A global review of recent studies (1994-2000) | 1 | 1
|
| 1 | 63 2002 AMBULATORY PEDIATRICS 2(4):330-336
Tilford JM
Cost-effectiveness analysis and emergency medical services for children: Issues and applications | 1 | 0
|
| 2 | 75 2002 PHARMACOECONOMICS 20(1):1-7
Beutels P; Edmunds WJ; Antonanzas F; De Wit GA; Evans D; Feilden R; Fendrick AM; Ginsberg GM; Glick HA; Mast E; Pechevis M; Van Doorslaer EKA; van Hout BA
Economic evaluation of vaccination programmes - A consensus statement focusing on viral hepatitis | 1 | 0
|
| 1 | 2 1997 HEALTH ECONOMICS 6(5):545-546
Drummond MF
Cost-effectiveness in health and medicine - Gold,MR, Siegel,JE, Russell,LB, Weinstein,MC | 0 | 0
|
| 2 | 21 1998 REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE 46(3):245-246
Moatti J
Preventing fatal diseases increases health care costs - Comments | 0 | 0
|
| 1 | 22 1999 FOOD POLICY 24(2-3):145-162
Kenkel DS; Manning W
Economic evaluation of nutrition policy Or, there's no such thing as a free lunch | 0 | 0
|
| 1 | 25 1999 JOURNAL OF CLINICAL PSYCHIATRY 60():32-37
Meltzer D
Perspective and the measurement of costs and benefits for cost- effectiveness analysis in schizophrenia | 0 | 0
|
| 3 | 30 1999 MEDICAL DECISION MAKING 19(4):381-382
Weinstein MC
Comment - Theoretically correct cost-effectiveness analysis | 0 | 0
|
| 1 | 36 2000 HEALTH POLICY 54(2):125-141
Bech M; Gyrd-Hansen D
Cost implications of routine mammography screening of women 50- 69 years in the County of Funen, Denmark | 0 | 0
|
| 1 | 39 2000 JOURNAL OF HEALTH ECONOMICS 19(5):719-730
Calcott P
Health care evaluation, utilitarianism and distortionary taxes | 0 | 0
|
| 2 | 44 2000 PHARMACOECONOMICS 18(2):185-200
Marissal JP; Selke B; Lebrun T
Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate | 0 | 0
|
| 2 | 47 2001 AMERICAN JOURNAL OF MANAGED CARE 7(2):S62-S75
McGhan WF
Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder | 0 | 0
|
| 1 | 49 2001 ARCHIVES OF INTERNAL MEDICINE 161(1):111-120
Weaver M; Krieger J; Castorina J; Walls M; Ciske S
Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines | 0 | 0
|
| 3 | 51 2001 EUROPEAN JOURNAL OF CANCER 37(14):1752-1758
Johnston K
Modelling the future costs of breast screening | 0 | 0
|
| 2 | 52 2001 EUROPEAN JOURNAL OF PUBLIC HEALTH 11(2):234-236
Brouwer WBF; Rutten FFH
Health economics - A bridge over troubled water | 0 | 0
|
| 3 | 55 2001 HEALTH ECONOMICS 10(6):499-508
Zivin JG
Cost-effectiveness analysis with risk aversion | 0 | 0
|
| 1 | 58 2001 JOURNAL OF HEALTH ECONOMICS 20(2):169-185
van Zon A; Muysken J
Health and endogenous growth | 0 | 0
|
| 4 | 62 2001 PHARMACOECONOMICS 19(9):901-916
Ekman M; Zethraeus N; Jonsson B
Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden - Analysis using data from the cardiac insufficiency bisoprolol study II trial | 0 | 0
|
| 1 | 64 2002 AMERICAN JOURNAL OF MANAGED CARE 8(1):45-53
Meenan RT; Goodman MJ; Fishman PA; Hornbrook MC; O'Keeffe-Rosetti MC; Bachman DJ
Issues in pooling administrative data for economic evaluation | 0 | 0
|
| 4 | 65 2002 AMERICAN JOURNAL OF PREVENTIVE MEDICINE 22(2):98-105
Phillips KA; Chen JL
Impact of the US panel on cost-effectiveness in health and medicine | 0 | 0
|
| 5 | 66 2002 BONE 31(1):26-31
Kanis JA; Johnell O; Oden A; De Laet C; Oglesby A; Jonsson B
Intervention thresholds for osteoporosis | 0 | 0
|
| 1 | 67 2002 CLINICA CHIMICA ACTA 315(1-2):31-40
Butler JRG
Economic evaluations of screening programs: a review of methods and results | 0 | 0
|
| 1 | 68 2002 HEALTH ECONOMICS 11(4):285-299
Nielson R; Gyrd-Hansen DT
Prenatal screening for cystic fibrosis: an economic analysis | 0 | 0
|
| 2 | 69 2002 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 287(13):1649-1650
Mason J; Eccles M; Freemantle N; Nazareth I; Haines A; Drummond M
The costs of making practice more cost-effective - Reply | 0 | 0
|
| 1 | 70 2002 JOURNAL OF HEALTH ECONOMICS 21(1):169-175
Blomqvist A
Defining the value of a statistical life: a comment | 0 | 0
|
| 3 | 71 2002 JOURNAL OF HEALTH ECONOMICS 21(2):181-195
Blomqvist A
QALYs, standard gambles, and the expected budget constraint | 0 | 0
|
| 4 | 72 2002 JOURNAL OF INTERNAL MEDICINE 251(6):508-517
Bjorholt I; Andersson FL; Kahan T; Ostergren J
The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study | 0 | 0
|
| 1 | 73 2002 JOURNAL OF NEUROIMAGING 12(2):148-152
Boyajian RA; Otis SM
Integration and added value of the modern noninvasive vascular laboratory in vascular diseases management | 0 | 0
|
| 2 | 74 2002 MEDICAL CARE 40(6):63-72
Etzioni R; Riley GF; Ramsey SD; Brown M
Measuring costs - Administrative claims data, clinical trials, and beyond | 0 | 0
|
| 1 | 76 2002 PHARMACOECONOMICS 20(2):101-108
Lindgren P; Jonsson B; Redaelli A; Radice D
Cost-effectiveness analysis of exemestane compared with Megestrol in advanced breast cancer - A model for Europe and Australia | 0 | 0
|
| 1 | 77 2002 SOCIAL PHILOSOPHY & POLICY 19(2):246-270
Rai AK
Pharmacogenetic interventions, orphan drugs, and distributive justice: The role of cost-benefit analysis | 0 | 0
|
| 2 | 78 2002 SOCIAL SCIENCE & MEDICINE 54(1):49-64
Dozet A; Lyttkens CH; Nystedt P
Health care for the elderly: two cases of technology diffusion | 0 | 0
|